General Information of the Protein
| Protein ID |
PT00907
|
||||
|---|---|---|---|---|---|
| Protein Name |
Dipeptidyl peptidase 4
|
||||
| Secondarily Protein Name |
ADABP
Adenosine deaminase complexing protein 2
Dipeptidyl peptidase IV
T-cell activation antigen CD26
TP103
Dipeptidyl peptidase IV membrane form
Dipeptidyl peptidase IV soluble form
|
||||
| Gene Name |
DPP4
|
||||
| Secondarily Gene Name |
ADCP2
CD26
|
||||
| Sequence |
MKTPWKVLLGLLGAAALVTIITVPVVLLNKGTDDATADSRKTYTLTDYLKNTYRLKLYSLRWISDHEYLYKQENNILVFNAEYGNSSVFLENSTFDEFGHSINDYSISPDGQFILLEYNYVKQWRHSYTASYDIYDLNKRQLITEERIPNNTQWVTWSPVGHKLAYVWNNDIYVKIEPNLPSYRITWTGKEDIIYNGITDWVYEEEVFSAYSALWWSPNGTFLAYAQFNDTEVPLIEYSFYSDESLQYPKTVRVPYPKAGAVNPTVKFFVVNTDSLSSVTNATSIQITAPASMLIGDHYLCDVTWATQERISLQWLRRIQNYSVMDICDYDESSGRWNCLVARQHIEMSTTGWVGRFRPSEPHFTLDGNSFYKIISNEEGYRHICYFQIDKKDCTFITKGTWEVIGIEALTSDYLYYISNEYKGMPGGRNLYKIQLSDYTKVTCLSCELNPERCQYYSVSFSKEAKYYQLRCSGPGLPLYTLHSSVNDKGLRVLEDNSALDKMLQNVQMPSKKLDFIILNETKFWYQMILPPHFDKSKKYPLLLDVYAGPCSQKADTVFRLNWATYLASTENIIVASFDGRGSGYQGDKIMHAINRRLGTFEVEDQIEAARQFSKMGFVDNKRIAIWGWSYGGYVTSMVLGSGSGVFKCGIAVAPVSRWEYYDSVYTERYMGLPTPEDNLDHYRNSTVMSRAENFKQVEYLLIHGTADDNVHFQQSAQISKALVDVGVDFQAMWYTDEDHGIASSTAHQHIYTHMSHFIKQCFSLP
Show/Hide
|
||||
| Organism |
Homo sapiens, Human
|
||||
| Protein Classification |
Enzyme
>
Protease
>
Serine protease
>
Serine protease SC clan
>
Serine protease S9B subfamily
|
||||
| Function |
Cell surface glycoprotein receptor involved in the costimulatory signal essential for T-cell receptor (TCR)-mediated T-cell activation (PubMed:10951221, PubMed:10900005, PubMed:11772392, PubMed:17287217). Acts as a positive regulator of T-cell coactivation, by binding at least ADA, CAV1, IGF2R, and PTPRC (PubMed:10951221, PubMed:10900005, PubMed:11772392, PubMed:14691230). Its binding to CAV1 and CARD11 induces T-cell proliferation and NF-kappa-B activation in a T-cell receptor/CD3-dependent manner (PubMed:17287217). Its interaction with ADA also regulates lymphocyte-epithelial cell adhesion (PubMed:11772392). In association with FAP is involved in the pericellular proteolysis of the extracellular matrix (ECM), the migration and invasion of endothelial cells into the ECM (PubMed:16651416, PubMed:10593948). May be involved in the promotion of lymphatic endothelial cells adhesion, migration and tube formation (PubMed:18708048). When overexpressed, enhanced cell proliferation, a process inhibited by GPC3 (PubMed:17549790). Acts also as a serine exopeptidase with a dipeptidyl peptidase activity that regulates various physiological processes by cleaving peptides in the circulation, including many chemokines, mitogenic growth factors, neuropeptides and peptide hormones such as brain natriuretic peptide 32 (PubMed:16254193, PubMed:10570924). Removes N-terminal dipeptides sequentially from polypeptides having unsubstituted N-termini provided that the penultimate residue is proline (PubMed:10593948).
Show/Hide
|
||||
| Uniprot ID |
Show/Hide
|
||||
| Ensembl ID | |||||
| HGNC ID | |||||
| Subcellular Location |
Secreted
|
||||
Map of Molecular Bioactivity Related to the Protein
|
Map of Molecular Bioactivity Related to the Protein Protein Cell Line Compound Bioactivity Value: <= 0.1 μM > 0.1 μM and <= 10 μM > 10 μM Imprecise Activity |
|
|---|
Table of Molecular Bioactivities Related to the Protein
Cell Line ID: CL000023 , BTI-Tn-5B1-4
Cell Line ID: CL000034 , Caco-2
Cell Line ID: CL000006 , HEK293
Cell Line ID: CL000090 , Schneider 2
Cell Line ID: CL000013 , Sf9
Biochemical Assays
Clinical Information about the Protein
Target 1 ( Dipeptidyl peptidase 4 (DPP-4) )
| Target Type | Successful Target | ||||
|---|---|---|---|---|---|
| Disease | 4 Target-related Diseases | 4 | |||
| 1 | Type-2 diabetes [ICD-11: 5A11] | ||||
| 2 | Diabetic complication [ICD-11: 5A2Y] | ||||
| 3 | Non-insulin dependent diabetes [ICD-11: 5A11] | ||||
| 4 | Metabolic disorder [ICD-11: 5C50-5D2Z] | ||||
| Approved Drug(s) | 6 Approved Drugs | 6 | |||
| 1 | Alogliptin | Approved | |||
| 2 | Anagliptin | Approved | |||
| 3 | Linagliptin | Approved | |||
| 4 | Saxagliptin | Approved | |||
| 5 | Vildagliptin | Approved | |||
| 6 | Sitagliptin | Approved | |||
| Clinical Trial Drug(s) | 6 Clinical Trial Drugs | 6 | |||
| 1 | Dutogliptin | Phase 3 | |||
| 2 | MK-3102 | Phase 3 | |||
| 3 | PF-00734200 | Phase 2 | |||
| 4 | DA-1229 | Phase 1 | |||
| 5 | Teneligliptin | Phase 1 | |||
| 6 | SYR-472 | Phase 3 | |||
| Discontinued Drug(s) | 4 Discontinued Drugs | 4 | |||
| 1 | NVP-DPP728 | Discontinued in Phase 2 | |||
| 2 | ABT-279 | Discontinued in Phase 1 | |||
| 3 | TAK-100 | Discontinued in Phase 1 | |||
| 4 | PT-630 | Terminated | |||
| Investigative Drug(s) | 1 Investigative Drug | 1 | |||
| 1 | KR-62436 | Investigative | |||